Htg Molecular Diagnostics Stock Working Capital
| HTGMDelisted Stock | USD 0.57 0.20 54.05% |
HTG Molecular Diagnostics fundamentals help investors to digest information that contributes to HTG Molecular's financial success or failures. It also enables traders to predict the movement of HTG Stock. The fundamental analysis module provides a way to measure HTG Molecular's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to HTG Molecular stock.
HTG |
HTG Molecular Diagnostics Company Working Capital Analysis
HTG Molecular's Working Capital is a measure of company efficiency and operating liquidity. The working capital is usually calculated by subtracting Current Liabilities from Current Assets. It is an important indicator of the firm ability to continue its normal operations without additional debt obligations. .
More About Working Capital | All Equity Analysis
Working Capital | = | Current Assets | - | Current Liabilities |
Current HTG Molecular Working Capital | 7.38 M |
Most of HTG Molecular's fundamental indicators, such as Working Capital, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, HTG Molecular Diagnostics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Working Capital can be positive or negative, depending on how much of current debt the company is carrying on its balance sheet. In general terms, companies that have a lot of working capital will experience more growth in the near future since they can expand and improve their operations using existing resources. On the other hand, companies with small or negative working capital may lack the funds necessary for growth or future operation. Working Capital also shows if the company has sufficient liquid resources to satisfy short-term liabilities and operational expenses.
CompetitionAccording to the company's disclosures, HTG Molecular Diagnostics has a Working Capital of 7.38 M. This is 98.27% lower than that of the Health Care Technology sector and 98.41% lower than that of the Health Care industry. The working capital for all United States stocks is 99.5% higher than that of the company.
HTG Working Capital Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses HTG Molecular's direct or indirect competition against its Working Capital to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of HTG Molecular could also be used in its relative valuation, which is a method of valuing HTG Molecular by comparing valuation metrics of similar companies.HTG Molecular is currently under evaluation in working capital category among its peers.
HTG Fundamentals
| Return On Equity | -3.43 | |||
| Return On Asset | -0.62 | |||
| Operating Margin | (3.15) % | |||
| Current Valuation | 2.56 M | |||
| Shares Outstanding | 2.21 M | |||
| Shares Owned By Insiders | 6.54 % | |||
| Shares Owned By Institutions | 0.74 % | |||
| Number Of Shares Shorted | 2.73 K | |||
| Price To Earning | (0.88) X | |||
| Price To Book | 6.26 X | |||
| Price To Sales | 1.06 X | |||
| Revenue | 6.37 M | |||
| Gross Profit | (2.01 M) | |||
| EBITDA | (20.14 M) | |||
| Net Income | (21.59 M) | |||
| Cash And Equivalents | 14.1 M | |||
| Cash Per Share | 1.28 X | |||
| Total Debt | 4.83 M | |||
| Debt To Equity | 2.52 % | |||
| Current Ratio | 1.90 X | |||
| Book Value Per Share | 0.21 X | |||
| Cash Flow From Operations | (18.41 M) | |||
| Short Ratio | 0.03 X | |||
| Earnings Per Share | (17.10) X | |||
| Target Price | 6.0 | |||
| Number Of Employees | 53 | |||
| Beta | 0.99 | |||
| Market Capitalization | 1.06 M | |||
| Total Asset | 17.78 M | |||
| Retained Earnings | (229.93 M) | |||
| Working Capital | 7.38 M | |||
| Current Asset | 34.86 M | |||
| Current Liabilities | 6.32 M | |||
| Z Score | -20.86 | |||
| Net Asset | 17.78 M |
About HTG Molecular Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze HTG Molecular Diagnostics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of HTG Molecular using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of HTG Molecular Diagnostics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. You can also try the Economic Indicators module to top statistical indicators that provide insights into how an economy is performing.
Other Consideration for investing in HTG Stock
If you are still planning to invest in HTG Molecular Diagnostics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the HTG Molecular's history and understand the potential risks before investing.
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities |